News Headlines

  1. Abbvie And Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement For ISB 2001, A First-In-Class CD38×BCMA×CD3 Trispecific Antibody 7/10/2025

    AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.

  2. Eurofarma Is The First Brazilian Company To Implement Körber's PAS-X MES For Improved Data Access, Traceability, And Regulatory Compliance 7/10/2025

    Eurofarma Laboratórios has become the first Brazilian company to migrate its entire production at its main plant in Itapevi, São Paulo, to Körber's PAS-X Manufacturing Execution System.

  3. Vita Therapeutics And I Peace Announced A Development Program To Generate iPS-Derived Differentiated Cells For Transplant Therapy With An Initial Focus On FSHD (Facioscapulohumeral Muscular Dystrophy) Using Universal iPS Cells 7/10/2025

    Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.

  4. Ofichem Acquires Avivia B.V. To Expand Formulation Development Capabilities 7/9/2025

    Ofichem Group has signed a definitive agreement to acquire Avivia B.V., a company specialized in formulation development based in Nijmegen, the Netherlands.

  5. Aenova Expands Its Advanced Technology Portfolio With Cutting-Edge Hot Melt Extrusion Platform 7/9/2025

    Aenova relies on various innovative technologies to improve the oral bioavailability of poorly soluble pharmaceutical active ingredients. These include a new hot melt extrusion platform, which Aenova has now introduced at its Regensburg site.

  6. Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract With European Country 7/9/2025

    Bavarian Nordic A/S today announced the award of a contract valued over DKK 200 million to supply its MVA-BN smallpox/mpox vaccine to a European country.

  7. Sartorius Stedim Biotech And Sensible Biotechnologies Partner To Scale Up Sensible's Unique Cell-Based mRNA Design And Manufacturing Platform 7/9/2025

    Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, and Sensible Biotechnologies, a pioneer in cell-based design and manufacturing of mRNA therapeutics, have signed a Memorandum of Understanding (MoU).

  8. Repligen Corporation & Univercells Technologies Partner TO Enable Real-Time Monitoring OF Viral Vector And Vaccine Biomanufacturing 7/9/2025

    Univercells Technologies, a Donaldson Life Sciences business and global provider of bioprocessing solutions, announced a collaboration with Repligen Corporation to integrate real-time monitoring capabilities and enhance the development and manufacturing of viral vectors and vaccines.

  9. Amarna Therapeutics And NorthX Biologics Finalize Agreement To Advance Nimvec™ AM510 Gene Therapy Toward Clinical Trials For Type 1 Diabetes 7/8/2025

    Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company pioneering transformative gene therapies, today announced the formalization of an agreement with NorthX Biologics, a leading biologics manufacturing partner, to accelerate the development of Nimvec™, Amarna’s next-generation gene therapy platform targeting immune-mediated diseases.

  10. Myrtelle Launches Manufacturing Of First-In-Class Gene Therapy For Canavan Disease In Strategic Alliance With Charles River And Viralgen 7/8/2025

    Myrtelle Inc. ("Myrtelle" or the "Company"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD).